logo
Desi Farms India Ltd.
17 Nov 2026, 06:27PM
Desi Farms reports delay in Q2FY27 and H1FY27 financial results due to first-time consolidation
BSE India
Desi Farms informs that it requires additional time to finalize its unaudited financial results for the quarter and half-year ended September 30, 2026. The delay stems from the acquisition of SNA Milk and Milk Products Limited and DFSU Farmer Connect Private Limited in July 2026 via a share swap arrangement. These entities now require first-time consolidation into the company's financial statements. This process involves complex accounting procedures, including intercompany reconciliation, intra-group transaction elimination, and acquisition accounting adjustments.
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 0.00 0.00 0.00 - -
EBITDA -0.04 -0.00 0.02 -751.16% -340.79%
Net Profit -0.04 -0.00 0.02 -751.16% -340.79%
EPS -0.02 -0.00 0.01 -900.00% -350.00%
* Standalone data
Maagh Advertising reports unaudited standalone and consolidated financial results for H1FY27
BSE India
Maagh Advertising submits its unaudited standalone and consolidated financial results for the half year ended September 30, 2026. The results received approval from the Audit Committee and the Board of Directors during meetings held on November 16, 2026. The filing is submitted in compliance with Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
Parmax Pharma reports revenue jump to Rs 139.5 crore for Q2FY27
BSE India
Parmax Pharma reports a significant 445.8% YoY jump in Q2FY27 revenue to Rs 139.5 crore, driven by a substantial rise in operating income to Rs 139.5 crore. The company's total income for the half-year ended September 30, 2026, reaches Rs 242.5 crore, compared to Rs 44.9 crore in the previous year. Higher expenses, including a cost of materials consumed at Rs 91.4 crore, impact the overall margins. Revenue from operations shows a strong upward trajectory from Rs 25.4 crore in Q2FY26 to the current period.
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 11.70 8.22 2.53 42.37% 362.47%
EBITDA 0.89 2.91 -1.58 -69.37% 156.29%
Op. profit margin(%) -11.60 10.08 -62.81 -215.04% 81.54%
Net Profit 0.17 2.20 -2.08 -92.13% 108.32%
EPS 0.25 5.88 -5.56 -95.75% 104.50%
* Standalone data
Parmax Pharma reports Q2FY27 revenue jump to Rs 139.5 crore driven by higher income
BSE India
Parmax Pharma reports a significant jump in Q2FY27 revenue from operations to Rs 13.95 crore, while total income reaches Rs 13.95 crore. The company records a substantial YoY increase in total income compared to Rs 2.54 crore in Q2FY26. Revenue growth is primarily supported by a surge in other income and increased operational activity. Cost of materials consumed stands at Rs 9.14 crore for the quarter.
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 11.70 8.22 2.53 42.37% 362.47%
EBITDA 0.89 2.91 -1.58 -69.37% 156.29%
Op. profit margin(%) -11.60 10.08 -62.81 -215.04% 81.54%
Net Profit 0.17 2.20 -2.08 -92.13% 108.32%
EPS 0.25 5.88 -5.56 -95.75% 104.50%
* Standalone data
Manas Properties submits revised H1FY27 financial results to rectify technical scanner error
BSE India
Manas Properties submits revised unaudited standalone financial results for the half year ended 30th September 2026 to rectify a scanner technical issue. The initial submission inadvertently missed the cash flow statement page during the filing on 13th November 2026. The company clarifies that the omission was a technical glitch rather than a willful default. The revised statements include the full cash flow statement and the Limited Review report adopted by the Board.
Amit International approves unaudited financial results for Q2FY27 and half-year ended September 30
BSE India
Amit International board approves the unaudited financial results for the quarter and half-year ended September 30, 2026. The announcement includes the Statement of Assets and Liabilities, Statement of Cash Flows, and the Limited Review Report from statutory auditors. The board meeting conducted on November 14, 2026, formalizes these periodic financial disclosures for regulatory compliance.
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 0.00 0.00 0.00 - -
EBITDA -0.04 -0.00 0.02 -751.16% -340.79%
Net Profit -0.04 -0.00 0.02 -751.16% -340.79%
EPS -0.02 -0.00 0.01 -900.00% -350.00%
* Standalone data
Seya Industries submits unaudited standalone financial results for Q2FY27 and H1FY27
BSE India
Seya Industries submits its unaudited standalone financial statements for the quarter and half-year ended September 30, 2026. The financial statements receive approval from the Interim Resolution Professional (IRP) based on an independent committee's recommendation. This filing includes the limited review report from the statutory auditors for the period.
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 0.00 0.00 0.00 - -
EBITDA 3.88 3.14 3.01 23.44% 29.00%
Net Profit -0.02 -0.71 -0.93 97.51% 98.08%
EPS -0.01 -0.27 -0.35 97.78% 98.28%
* Standalone data
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 16.01 21.93 10.11 -27.02% 58.31%
EBITDA 0.78 2.29 1.02 -65.74% -23.13%
Op. profit margin(%) 3.61 5.64 9.38 -36.07% -61.53%
Net Profit 0.24 1.67 0.38 -85.92% -37.89%
EPS 0.20 1.45 0.34 -86.21% -41.18%
* Consolidated data
K G Denim reports Q2FY27 results and Independent Director D Kumaravel tenders resignation
BSE India
K G Denim submits its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The announcement includes a limited review report from auditors covering segment-wise performance. Additionally, Independent Director D Kumaravel tenders his resignation effective November 13, 2026, citing personal reasons. The company also notes the continuation of its Non-Executive Chairman beyond the age of 75 years.
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 10.48 4.86 8.04 115.64% 30.35%
EBITDA -5.57 18.39 12.90 -130.29% -143.18%
Op. profit margin(%) -35.59 -86.01 156.22 58.62% -122.78%
Net Profit -13.05 8.60 1.83 -251.74% -813.11%
EPS -5.08 3.35 0.71 -251.64% -812.48%
* Consolidated data